J.B. Chemicals & Pharmaceuticals
JBCHEPHARM
J.B. Chemicals & Pharmaceuticals Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 15,031 |
| Weekly | 5.16% | 4,24,789 |
| Monthly | 10.82% | 48,59,632 |
J.B. Chemicals & Pharmaceuticals Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| JBCHEPHARM | - | 5.16% | 10.82% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
J.B. Chemicals & Pharmaceuticals Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| JBCHEPHARM | 32.66 | 5.92 | 24.87 | 19.33 | 24.76 | 0.84 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
J.B. Chemicals & Pharmaceuticals Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 17.22% | -16.59% | 19.33% | 24.76% |
| FY '20-21 | 15.20% | 65.70% | 27.57% | 36.43% |
| FY '19-20 | 8.65% | 43.86% | 18.49% | 23.33% |
J.B. Chemicals & Pharmaceuticals Shareholding Pattern
J.B. Chemicals & Pharmaceuticals Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 2,307.06 | 1,781.39 | 565.10 | 373.52 |
| FY '20-21 | 1,967.26 | 1,413.01 | 670.52 | 447.80 |
| FY '19-20 | 1,707.74 | 1,334.83 | 423.14 | 270.27 |
J.B. Chemicals & Pharmaceuticals Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| JBCHEPHARM | 2,307.06 | 1,781.39 | 565.10 | 373.52 |
| AJANTPHARM | 3,240.82 | 2,330.72 | 1,037.80 | 716.27 |
| LAURUSLABS | 4,821.31 | 3,467.49 | 1,372.24 | 791.26 |
J.B. Chemicals & Pharmaceuticals Share Price
J. B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company. The company's field of activity is the production and distribution of various medicines, herbal preparations and active ingredients (API). It is engaged in the production of product development services. The company offers a variety of products and formulations in various therapeutic categories, including gastroenterology, hypertension, dermatology, nephrology, respiratory infections, virology, diabetes, wound care, anti-infectives, pharmacovigilance and nicotine replacement therapy (NRT). Its product range includes lozenges, which include centre-filled, soft-centre lozenges, centre-filled, powder lozenges, herbal tablets and medicinal preparations. Products in this API include diclofenac sodium, diclofenac diethylamine, diclofenac acid, diclofenac potassium, nifedipine, atenolol, cilnidipine, and ciprofloxacin HCl. The company also owns the Razel (Rousvastatin) franchise in India and Nepal.